title: Drug discovery for autism spectrum disorder: challenges and opportunities.
abstract: The rising rates of autism spectrum disorder (ASD) and the lack of effective medications to treat its core symptoms have led to an increased sense of urgency to identify therapies for this group of neurodevelopmental conditions. Developing drugs for ASD, however, has been challenging because of a limited understanding of its pathophysiology, difficulties in modelling the disease in vitro and in vivo, the heterogeneity of symptoms, and the dearth of prior experience in clinical development. In the past few years these challenges have been mitigated by considerable advances in our understanding of forms of ASD caused by single-gene alterations, such as fragile X syndrome and tuberous sclerosis. In these cases we have gained insights into the pathophysiological mechanisms underlying these conditions. In addition, they have aided in the development of animal models and compounds with the potential for disease modification in clinical development. Moreover, genetic studies are illuminating the molecular pathophysiology of ASD, and new tools such as induced pluripotent stem cells offer novel possibilities for drug screening and disease diagnostics. Finally, large-scale collaborations between academia and industry are starting to address some of the key barriers to developing drugs for ASD. Here, we propose a conceptual framework for drug discovery in ASD encompassing target identification, drug profiling and considerations for clinical trials in this novel area.
authors.affiliation: F. Hoffmann-La Roche, pRED, Pharma Research and Early Development, DTA Neuroscience, Grenzacherstrasse 124, 4070 Basel, Switzerland.
authors.forename: Anirvan
authors.initials: A
authors.lastname: Ghosh
authors.forename: Aubin
authors.initials: A
authors.lastname: Michalon
authors.forename: Lothar
authors.initials: L
authors.lastname: Lindemann
authors.forename: Paulo
authors.initials: P
authors.lastname: Fontoura
authors.forename: Luca
authors.initials: L
authors.lastname: Santarelli
mesh_terms: D000818:Animals; D002648:Child; D002659:Child Development Disorders, Pervasive / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D002986:Clinical Trials as Topic; D003299:Cooperative Behavior; D004195:Disease Models, Animal; D015195:Drug Design; D055808:Drug Discovery; D004345:Drug Industry / Q000379:methods / Q000458:organization & administration; D006801:Humans; D058990:Molecular Targeted Therapy